Crizotinib-Associated Renal Cysts: A Case Series

Abstract

Crizotinib is an anaplastic lymphoma kinase (ALK) inhibitor, used as a targeted chemotherapeutic agent in ALK-positive cases of nonsmall cell lung carcinoma. Although uncommon, it may be associated with the formation of new renal cysts, which may be simple or complex, or the enlargement of preexisting simple renal cysts or their transformation into complex cysts. These cysts usually regress partially or completely but may rarely enlarge over time or get complicated by infection or abscess formation. Such cases may even require dose reduction or withholding crizotinib. Although documented in clinical literature, this entity is not well known among radiologists. Knowledge of this entity helps in preventing erroneous diagnosis of the new kidney “lesion” as metastasis or disease progression and avoids an unnecessary biopsy. We describe a series of four cases which developed complex renal cysts during treatment with crizotinib to demonstrate this point.

Keywords

crizotinib-associated renal cyst - anaplastic lymphoma kinase - nonsmall-cell lung cancer - complex cyst

• References

• 1 Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008; 83 (05) 584-594
• 2 Desai SS, Shah AS, Prabhash K, Jambhekar NA. A year of anaplastic large cell kinase testing for lung carcinoma: pathological and technical perspectives. Indian J. Cancer 2013; 50 (02) 80-86
• 3 Crizotinib Label FDA. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202570s006lbl.pdf
• 4 Lin YT, Wang YF, Yang JC. et al. Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer. J Thorac Oncol 2014; 9 (11) 1720-1725
• 5 Schnell P, Bartlett CH, Solomon BJ. et al. Complex renal cysts associated with crizotinib treatment. Cancer Med 2015; 4 (06) 887-896
• 6 Yoneshima Y, Okamoto I, Arimura-Omori M. et al. Infected complex renal cysts during crizotinib therapy in a patient with non-small cell lung cancer positive for ALK rearrangement. Invest New Drugs 2015; 33 (02) 510-512
• 7 Cameron LB, Jiang DHS, Moodie K, Mitchell C, Solomon B, Parameswaran BK. Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution. Cancer Imaging 2017; 17 (01) 7
• 8 Schiller JH, Harrington D, Belani CP. et al. Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346 (02) 92-98
• 9 Chan BA, Hughes BGM. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res 2015; 4 (01) 36-54
• 10 Solomon BJ, Mok T, Kim DW. et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer, for the PROFILE 1014 investigators. N Engl J Med 2014; 371: 2167-2177
• 11 Horie S, Higashihara E, Nutahara K. et al. Mediation of renal cyst formation by hepatocyte growth factor. Lancet 1994; 344 (8925) 789-791
• 12 Klempner SJ, Aubin G, Dash A, Ou SH. Spontaneous regression of crizotinib-associated complex renal cysts during continuous crizotinib treatment. Oncologist 2014; 19 (09) 1008-1010
• 13 Jia JB, Lall C, Tirkes T, Gulati R, Lamba R, Goodwin SC. Chemotherapy-related complications in the kidneys and collecting system: an imaging perspective. Insights Imaging 2015; 6 (04) 479-487
• 14 Israel GM, Bosniak MA. How I do it: evaluating renal masses. Radiology 2005; 236 (02) 441-450
• 15 Scatena C, Comin CE, Lapini A, Raspollini MR. Renal metastasis from pulmonary adenocarcinoma: the pathologist’s approach to an uncommon finding: case report and review of the literature. Appl Immunohistochem Mol Morphol 2013; 21 (05) 460-4631
• 16 Honda H, Coffman CE, Berbaum KS, Barloon TJ, Masuda K. CT analysis of metastatic neoplasms of the kidney. Comparison with primary renal cell carcinoma. Acta Radiol 1992; 33 (01) 39-44
• 17 Voci SL, Gottlieb RH, Fultz PJ. et al. Delayed computed tomographic characterization of renal masses: preliminary experience. Abdom Imaging 2000; 25 (03) 317-321